Ensuring psychedelic treatments and research do not leave anyone behind.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – January 01, 2024
Source: PubMed
Summary
As psychedelic treatments gain momentum in mental healthcare, access disparities threaten to exclude marginalized communities. Historically underserved groups face multiple barriers to participating in clinical trials and receiving innovative treatments. Targeted outreach, culturally-informed protocols, and inclusive research design can help ensure these breakthrough therapies benefit all populations equitably.
Abstract
Psychedelics are a promising approach to caring for persons living with severe mental illness. However, as with all clinical treatments and research in the US, health equity concerns must be considered and addressed. Ensuring health equity and health justice in psychedelic care delivery and research will require strategies to not only reduce disparities and preempt future disparities among minoritized and marginalized populations.